SCHEMBL3854350

SCHEMBL3854350

COc1ccc2ncc(CCC(=O)O)cc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.57
HPGD P15428 2/20 0.57
F2 P00734 1/20 0.57
GLA P06280 1/20 0.57
CYP1A2 P05177 2/20 0.52
KDM4E B2RXH2 2/20 0.52
LMNA P02545 2/20 0.52
NPC1 O15118 1/20 0.52
TP53 P04637 1/20 0.52
CYP3A4 P08684 1/20 0.52
MAPT P10636 1/20 0.52
MAOA P21397 1/20 0.52
SLC6A2 P23975 1/20 0.52
RAB9A P51151 1/20 0.52
SLC6A3 Q01959 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
PTGS1 P23219 1/20 0.51
AKR1C3 P42330 1/20 0.51
AKR1C2 P52895 1/20 0.51
FFAR1 O14842 5/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31735898 0.86 PTGS1 (0.66) ALDH1A1HPGDF2GLAKDM4E
SCHEMBL8885378 0.83 ALDH1A1 (0.48) ALDH1A1HPGDF2GLACYP1A2
SCHEMBL1403565 0.81 CYP1A2 (0.77) ALDH1A1HPGDCYP1A2KDM4ELMNA
SCHEMBL8882652 0.80 ALDH1A1 (0.57) ALDH1A1HPGDF2GLAKDM4E
Ethane SCHEMBL27947703 0.79 ALDH1A1 (0.56) ALDH1A1HPGDF2GLAKDM4E
SCHEMBL9814937 0.78 PDGFRB (0.55) ALDH1A1HPGDF2GLAKDM4E
SCHEMBL8883782 0.78 ALDH1A1 (0.56) ALDH1A1HPGDF2GLACYP1A2
SCHEMBL8883784 0.78 ALDH1A1 (0.56) ALDH1A1HPGDF2GLACYP1A2
SCHEMBL2697677 0.78 PTGS1 (0.66) ALDH1A1HPGDF2GLACYP1A2
SCHEMBL11996262 0.77 PDGFRB (0.54) ALDH1A1HPGDF2GLAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1687276-B1 NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES NOVEXEL (FR) 2009-10-14 EP disclosed
US-7396934-B2 Process for preparing 3-fluoroquinolines NOVEXEL (FR) 2008-07-08 US disclosed
EP-1687276-A1 NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES NOVEXEL (FR) 2006-08-09 EP disclosed
US-20050182259-A1 Subjecting a substituted quinoline-3-carboxamide compound to Hofmann degradation to obtain amine derivative, forming diazonium salt by reacting amine derivative with borontrifluoride-ethyl ether complex, heating to form 3-fluoroquinolines; intermediate for forming antibacterial compound AVENTIS PHARMA S.A. (US) 2005-08-18 US disclosed
WO-2005049575-A1 NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES NOVEXEL (FR) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182259-A1 Subjecting a substituted quinoline-3-carboxamide compound to Hofmann degradation to obtain amine derivative, forming diazonium salt by reacting amine derivative with borontrifluoride-ethyl ether complex, heating to form 3-fluoroquinolines; intermediate for forming antibacterial compound QRFPR, NQO2, DHX35 ALDH1A1 2137/4885HPGD 2236/4885F2 3610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.